The REACH Intervention for Caregivers of Veterans and Service Members With TBI
This randomized waitlist control trial will evaluate the effects of a psychoeducational intervention called Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) to decrease caregiver strain (primary outcome) and improve caregiver self-efficacy, anxiety, depression, and health care frustra
| Condition(s) | Traumatic Brain Injury, Caregiver |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This randomized waitlist control trial will evaluate the effects of a psychoeducational intervention called Resources for Enhancing All Caregivers' Health - Traumatic Brain Injury (REACH TBI) to decrease caregiver strain (primary outcome) and improve caregiver self-efficacy, anxiety, depression, and health care frustrations (secondary outcomes). This study will modify and adapt an award-winning caregiver intervention, Resources for Enhancing All Caregivers Health in the Department of Veterans Affairs (REACH VA), to support the needs of Caregivers of Veterans and Service Members with TBI. |
| Who can participate | Inclusion Criteria: To be eligible for the study, the participant must: * identify as a primary caregiver for a V/SM who sustained a TBI at least 6 months prior; * identify as a primary caregiver who has provided care for a V/SM with TBI for at least 6 months; * provide some level of daily supervision or assistance with either a physical, cognitive, or behavioral issue they think is likely related to TBI; * believe that at least half of their caregiving responsibilities are likely related to TBI rather than another health condition(s); and * endorse a score of at least high burden (a score of 8 or higher) on the Zarit Burden Inventory-4. Exclusion Criteria: * no telephone; * current diagnosis of schizophrenia or other major mental illness; * auditory impairment that would make telephone us |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Virginia |
| Locations | Tampa, Florida, United States |
| Start date | 2024-07-12 |
| NCT ID | NCT06111794 |
| Official listing | https://clinicaltrials.gov/study/NCT06111794 |